Contrasting Affymax (OTCMKTS:AFFY) and Curis (NASDAQ:CRIS)

Curis (NASDAQ:CRIS) and Affymax (OTCMKTS:AFFY) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Valuation and Earnings

This table compares Curis and Affymax”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$4.31 million	0.77	-$7.58 million	($14.22)	-0.11
Affymax	N/A	N/A	N/A	N/A	N/A

Affymax has lower revenue, but higher earnings than Curis.

Profitability

This table compares Curis and Affymax’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	-2,365.94%	-200.88%
Affymax	N/A	N/A	N/A

Risk & Volatility

Curis has a beta of 3.13, suggesting that its stock price is 213% more volatile than the S&P 500. Comparatively, Affymax has a beta of 7.32, suggesting that its stock price is 632% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Curis and Affymax, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	2	0	1	0	1.67
Affymax	0	0	0	0	0.00

Curis presently has a consensus price target of $43.00, indicating a potential upside of 2,604.40%. Given Curis’ stronger consensus rating and higher possible upside, equities analysts plainly believe Curis is more favorable than Affymax.

Institutional and Insider Ownership

30.0% of Curis shares are owned by institutional investors. 5.8% of Curis shares are owned by company insiders. Comparatively, 1.5% of Affymax shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Curis beats Affymax on 6 of the 10 factors compared between the two stocks.

About Curis

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

About Affymax

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.